Cellectis SA

CLLS · NYSE

$0.98+$0.005 (+0.51%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $0.975

Latest news

Press releaseOct 15, 11:00 AM ETGlobe Newswire
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Press releaseOct 15, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Press releaseOct 15, 9:00 AM ETGlobe Newswire
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Press releaseOct 14, 4:54 PM ETGlobe Newswire
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Press releaseOct 13, 5:03 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
Press releaseOct 8, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Press releaseOct 6, 4:33 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Press releaseSep 24, 4:17 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Press releaseSep 22, 6:08 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
Press releaseSep 19, 7:31 PM ETBusiness Wire
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Press releaseSep 17, 2:45 PM ETGlobe Newswire
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
Press releaseSep 17, 11:00 AM ETBusiness Wire
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Press releaseSep 17, 9:00 AM ETBusiness Wire
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Press releaseSep 16, 5:50 PM ETBusiness Wire
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
NewsSep 14, 12:09 PM ETAvi Kapoor
Crude Oil Jumps 3%; Corning Shares Move Lower
NewsSep 14, 10:07 AM ETAvi Kapoor
Nasdaq Down Over 200 Points; Cellectis Shares Plunge
NewsSep 14, 9:39 AM ETVandana Singh
Cellectis Pivots to Gene Editing in Major Overhaul
Press releaseSep 14, 2:40 AM ETGlobe Newswire
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Press releaseAug 6, 4:30 PM ETGlobe Newswire
Cellectis Reports Financial Results for the Second Quarter 2026
Press releaseJun 11, 2:40 AM ETGlobe Newswire
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Press releaseJun 9, 4:30 PM ETGlobe Newswire
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Press releaseMay 12, 9:30 AM ETGlobe Newswire
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Press releaseMay 11, 4:30 PM ETGlobe Newswire
Cellectis Reports Financial Results for the First Quarter 2026
NewsMay 11, 7:11 AM ET
Earnings Scheduled For May 11, 2026
Press releaseMay 4, 4:30 PM ETGlobe Newswire
Cellectis to Report First Quarter Financial Results on May 11, 2026
Press releaseApr 13, 4:30 PM ETGlobe Newswire
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform
NewsApr 13, 12:59 PM ETVandana Singh
Allogene Therapeutics Stock Hits 52-Week High - Here's Why
NewsMar 19, 7:11 AM ET
Earnings Scheduled For March 19, 2026
Press releaseMar 12, 4:30 PM ETGlobe Newswire
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Press releaseJan 8, 4:30 PM ETGlobe Newswire
Cellectis Announces 2026 Strategy and Catalysts
NewsDec 23, 9:47 AM ETAvi Kapoor
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
NewsDec 16, 1:09 PM ETVandana Singh
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Press releaseDec 15, 5:39 PM ETGlobe Newswire
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Press releaseDec 8, 1:30 AM ETGlobe Newswire
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
NewsNov 21, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsNov 7, 4:32 PM ET
Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate
Press releaseNov 7, 4:30 PM ETGlobe Newswire
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsNov 7, 6:11 AM ET
Earnings Scheduled For November 7, 2025
NewsOct 20, 8:10 AM ETAvi Kapoor
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsSep 29, 8:06 AM ETAvi Kapoor
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsSep 29, 5:07 AM ETAvi Kapoor
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
NewsMar 14, 8:10 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMar 14, 5:08 AM ETAvi Kapoor
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Press releaseMar 13, 6:07 PM ETGlobe Newswire
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Crude Oil Jumps 3%; Corning Shares Move Lower

Nasdaq Down Over 200 Points; Cellectis Shares Plunge

Cellectis Pivots to Gene Editing in Major Overhaul

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Cellectis Reports Financial Results for the Second Quarter 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

Cellectis Reports Financial Results for the First Quarter 2026

Earnings Scheduled For May 11, 2026

Cellectis to Report First Quarter Financial Results on May 11, 2026

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform

Allogene Therapeutics Stock Hits 52-Week High - Here's Why

Earnings Scheduled For March 19, 2026

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Cellectis Announces 2026 Strategy and Catalysts

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

12 Health Care Stocks Moving In Friday's After-Market Session

Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 7, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update